Get started

Medical

Short the Red box :OWe have a good shorting Opp here. Its showing signs of reversal on most timeframes especially the larger ones such at the Month, Week and Daily. Noone can see 3-4 years into the future right? Well I'm no different so dont take this as financial advice more of just a hey this looks ok to me sort of thing. Ive taken the time to give you a Fan, a Triangle, and major resistance and support levels on larger time frames. Take the time do your own research but hope this helps guide some in the right direction Enjoy :) Purple is Monthy Yellow is weekly White is Heavy resistance/support lines due to large moves up/down Red Box: Short Area Overall Target it is 18-19, with potential to break through to 7-8
NYSE:BSXShort
by CryptoLeroy
CELLECTIS LONG TERM BUYHi Guys Following my ideas redarding #cellectis. A promising french biotech company that already celebrates hugh success with "their" ucart19 against leukemia. Check out my thoughts and join the conversatioin. TA: - Double bottom which is normally an indicator for a reversal. - higher high and higher low - Oversold Stoch RSI (4hr) - Rising MACD Fundamentals: - CASH POSITION OF $ 452M AS OF DECEMBER 31, 2018 COMPARED TO $ 297M AS OF DECEMBER 31, 2017 - CELLECTIS, THROUGH ITS NEW SUBSIDIARY CELLECTIS BIOLOGICS, INC., ENTERED INTO A LEASE AGREEMENT TO BUILD A MANUFACTURING FACILITY IN NORTH CAROLINA, ADVANCING COMMERCIALIZATION CAPABILITIES FOR ITS UCART PORTFOLIO - UCART123 IN PHASE 1 DOSE ESCALATION CLINICAL TRIAL ONGOING FOR AML - UCART22 RECEIVED FDA AND IRB APPROVALS FOR PHASE 1 DOSE ESCALATION CLINICAL TRIAL IN B-ALL PATIENTS - UCART19 ASH ABSTRACT BY PARTNERS SERVIER AND ALLOGENE SHOWED CONTINUED PROGRESS OF FIRST CLINICAL ALLOGENEIC CAR T-CELL PROGRAM FOR ALL ADULT AND PEDIATRIC PATIENTS. MILESTONES PAYMENT CONTRACT WITH PFIZER AND SERVIER UPCOMING CHECK OUT ALSO THIS AMAZING STORY. WE'RE ABOUT TO CHANCE THE FUTURE BUT ITS A LONG WAY TO GO google: layla cellectis
NASDAQ:CLLSLong
by don_padrone
Penumbra: Richly-valued but trades well after earningsNov 5th, 3:12 pm $PEN Q3 top line beat of $111.8M vs consensus $102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M Nov 6th, 9:15 am $PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for $JNJ $MDT or even $EW Wells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT. PEN
NYSE:PENLong
by KevinBCookca
Tetra Tech Corp. on 3rd falling wedge, await 7 life cat bouncewatching for entry, pulse, dead cat falling wedge for 3rd cycle (2014, 2016, 2018)...TBD About: Terra Tech Corp. operates as a vertically integrated cannabis-focused agriculture company. The company operates in two segments, Herbs and Produce Products; and Cannabis Dispensary, Cultivation and Production. The Herbs and Produce Products segment offers hydroponic herbs, produce, and floral products. The Cannabis Dispensary, Cultivation and Production segment operates medical marijuana retail and adult use dispensaries under the name Blum, which provides a selection of medical and adult use cannabis products, such as flowers, concentrates, and edibles; and produces and sells a line of medical and adult use cannabis flowers, as well as a line of medical and adult use cannabis-extracted products comprising concentrates, cartridges, vape pens, and wax products in California and Nevada. Terra Tech Corp. was founded in 2010 and is headquartered in Irvine, California. $122M Cap, down 52% YTD, $38.5M rev. 7-1YOY, rev gr. 38%, 127K shares bought by insiders last 2 yr. (strong), Inst. MF hold 0%, while wealth manag. <1%, so mostly private investors, so high upside if legallized, earnings range -0.30 (3/8) to 0 (1/8), so still not profitable pop needed (11/7/18 next announcement). 8.7.18 was -0.17. The rapidly rising demand for Cannabidiol (CBD) and Hemp based products is showing no signs of slowing down as expectations to push both markets into new territories with exploding sales value in the next coming years. The global industrial hemp market size is expected to reach USD $10.6 billion by 2025, according to a new report by Grand View Research, Inc. and the market is anticipated to expand at a CAGR of 14.0%. The North American CBD market is primed for expansive growth across its three primary sectors, hemp-derived CBD, marijuana-derived CBD and pharmaceutical CBD. With recent developments and advancements in the hemp industry, farmers across the country are turning their attention to commercialization looking for the road to profitability. Increasing R&D activities to develop perfect agronomy and new genetics of crops to obtain high yield and improved product quality are expected to have a positive impact on CBD - Hemp production. Active Companies from around the market with current developments this week include: Marijuana Company of America (MCOA), Inc., GrowLife (PHOT), Inc. MPX Bioceutical Corporation (CSE:MPX) (OTC:MPXEF), Kush Bottles, Inc.(KSHB), Terra Tech Corp (TRTC)
TLong
by Pokethebear
CBIS Pulse is faint but pulsing with research quivers...Watch CCI momentum with MACD here. . . future profits and earnings TBD. Await patents and studies. Expect they'll eventually have to sell the farm here to pay for all the cannabis / hemp studies. Ent Value / Mkt Value is 1.02. A new medical advisory board for new medical products. One patent issued 2017 for treatment of neurobahaviors and could lead to positive litigation...TBD. This is a watch and wait scenerio for entry...@pokethebear Studies mainly on Endogenous cannabinnoid family, which are produced in our bodies, vs natural occuring phytocannabinoids from cannabis, or made synthetically. CBIS studies may be specific to proving scientific value as neuromodulators and their absorption/binding to the our bodies fatty lipid areas/tissues and possibly dosage. If there's a pHD in the room to help confirm wording here, but the study and health benefits of CBD, CBDA, CBG, CBGA, THC, THCA, 9-THC, 9-THCA, 8-THC and THCV. Aka proving the science to the F&DA each endocannabinoid does something specific (sleep aid, pain releif, epileptic med., ADHD/ADD med., reduce inflamation, anxiety, psoriasis (skin inflammation), slows bacterial growth, inhibit cancer cells (first study published), stimulate appetite, reduce vomiting/diarrhea, and several other benefits.
CLong
by Pokethebear
Biogen Earnings Swing July 2018Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018. Although the clinical trial's success was certainly reason for bullish sentiment, it ran too far too fast and indicators pointed towards to a sell off. I thus opened put options on July 9, expiring July 13 2018 (currently in the money). We are now only about two weeks away from Biogen's earning report. After studying historical data and charts, I've found that there is often a sell off prior to earnings OR there is a run up then a slight sell off right before the earnings date. I've annotated the chart with periods that indicate this. In this case, I believe downward momentum will continue followed by a slight rally pre-earnings then a sell off. Opening JUL20 puts may be a smart move at this time. In the long term, Biogen -0.21% is very scalable and overall is very promising. I agree with Citi's PT of 371. www.wsj.com
NASDAQ:BIIBShort
by UnknownUnicorn2997486
$CELZ Continues North with Accelerating Accumulation$CELZ is currently on a clear and clean breakout in anticipation of the May 18th- 21st Presentation at the American Urological Association Convention in San Francisco. An 8K was released recently showing that shares were issued at .10 and as high as .30 levels The following link shows that the CEO has been buying on the way up as well: backend.otcmarkets.com Look who covered $OWCP (Which ran from .003 to >> $3.05) and has been covering CELZ since Feb 18, 2018 (PPS @ .0094 at that time) CORRELATION? ;-) ----> t.co Also forgot to mention the debt is almost completely eliminated from the books :-)
CLong
by StockGuild
4
$CELZ Begins Breaking out on High buy Volume on News Release$CELZ broke above prior high on the last leg after a release of 8-Ks showing the clearing up of the rest of the company's debt and notes. Item 1.01 Entry into a Material Definitive Agreement Effective April 11, 2018, Creative Medical Technology Holdings, Inc. (the “ Company ”) amended promissory notes issued by it and by its operating subsidiary, Creative Medical Technology, Inc., to Creative Medical Health, Inc. (“ CMH ”), the parent of the Company, to permit the conversion of the notes into restricted shares of common stock of the Company. The 8% promissory notes were originally issued February 2, 2016, in the principal amount of $50,000, on May 1, 2016, in the principal amount of $50,000, and on May 18, 2016, in the principal amount of $25,000. The conversion formula on the principal and accrued interest on the amended notes is 120% of the 30-day volume weighted average price (VWAP) for the Company’s common stock traded March 1, 2018 through March 30, 2018. Immediately upon amendment of the notes, CMH converted the total outstanding principal and interest of the notes, which was $136,003. The VWAP for the 30-day period ended March 30, 2018, was $0.0138 and the number of shares issued to CMH for the conversion was 9,855,290 restricted common shares. Item 3.02 Unregistered Sales of Equity Securities In connection with the conversion of the notes disclosed under Item 1.01 above, the Company issued 9,855,290 shares of common stock to CMH without registration. The issuance of these securities was made pursuant to Rule 506(b) of Regulation D promulgated by the SEC under the Securities Act as a transaction not involving any public offering. No selling commissions or other remuneration were paid in connection with the issuance of these shares. Item 8.01 Other Events On April 12, 2018, the Company issued a press release announcing the amendment to the CMH notes and the conversion of the notes into common stock of the Company. From April 12, 2018 through April 19, 2018, we issued an aggregate of 114,017,952 shares upon the conversions of outstanding notes and 15,009,325 shares upon the cashless exercise of outstanding warrants. These conversions were made pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933. As a result of these issuances, we have outstanding 609,062,989 shares of common stock as of April 19, 2018.
CLong
by StockGuild
Mad Breakout to $65? Subtle Climb to $60? Quiet Retrace to $53?Oh Novanta. So many possibilities for such a great company. Please forgive the maddening amount of clustered lines. The primary trend line is massive and seemingly unstoppable for a reason. Even though it's gone parabolic, its story is rock solid and almost sexy with everything they have a hand in. As a leader in medical and advanced, industrial markets, Novanta went through a period of optimization several years ago, is currently in organic growth mode and is accelerating its scale from now until 2020 in order to DOUBLE their annual revenue. Oh, and as of their last public statement, they're still on track to do so. Quality products, leadership and personnel (over 375 engineers), coupled with proprietary technologies and over 400 patents, Novanta maintains a stoic and disciplined M&A schedule in order to maintain its edge and continue to innovate by divesting around 9% of revenue in R&D. The crossover between their sectors is astounding. Organic growth, momentum, acquisitions, a great M&A pipeline and leadership positions across key medical and industrial markets are providing, as Matthijs Glastra said, "...a solid foundation for sustainable, profitable growth." If you want a laser, robotics and high level medical play, this is it. Hold Novanta long term. Short term, if you're looking to just trade and not invest, there's been some massive momentum up from the previously, consistent levels held all of April. Based on how the stock has bounced off its bottom trend line, it was a good period of accumulation leading up to another spurt of gains towards the $58+ level. If it should shoot past this and hit what could easily be $65 (based off the previous $15+ jumps) sell immediately, because everyone else obviously did, twice. A retrace back to $53 off this momentum isn't bad and will surely hold or prep for the bounce back up to the $60 range outlined above.
NASDAQ:NOVTLong
by N3utra
Hi-Tech Medical+Robotics Play w/ $10 Stable, Transition RangeWith brand recognition and consistent sales in place, Mazor has stated that 2018 will be a transition year for them, not growth. Therefore, expect the company to aim for stability as it continues to spread its products. Per the last call: "2018 is expected to be a year of transition and our performance is expected to be driven primarily by increased revenues from the expanding installed base. Long-term, we would anticipate the installed base to expand considerably during the length of the global distribution agreement. Over the next five years, the largest result is a cumulative purchase of hundreds of Mazor X systems, which are expected to significantly accelerate procedure volume and growth." Overall trend lines have been followed from 2017 into 2018 in a balanced manner. Some weakness definitely showed up after such a quick run-up into the -now- low part of this year's fib chart. A good period of accumulation presented itself before another push higher in January gave it momentum (along with everything else in the market). February hit, but the stock did not tumble horribly. It had one more push higher that went way beyond what anyone, anywhere was expecting. Forums were happily confused. As such, a LOT of profit taking took place and rightfully so after all the volatility that had been in play. Regardless, the company's fundamentals have not changed and the stock is now back to its previous, stable 2018 levels. This is an excellent range to start a small position, as I expect the stock to continue trading back up close to $70 again with positive market momentum. Anything around the $56 level, where the stock has successfully bounced off of, is great for accumulation. A great company with an excellent product, vision and fundamentals makes holding this for stability within its range (and with opportunities for breakouts with ANY good news) a great pick for 2018. Technical trading within its $10 range ($58-68) is great for those who can time the market. --Additional Backstory-- Mazor is a hi-tech, medical robotics company that specializes in creating systems for assistance during spinal surgery. Everyone knows that surgery is an expensive process and back surgery is extremely costly, difficult and more common than we'd care to imagine. The two systems that Mazor has developed and begun selling (in conjunction with Medtronic) are state of the art and well known within their field. While 2017 was quiet at first, the company began to grow in spurts with a huge push, in part from Medtronic, near the end of the year.
MLong
by N3utra
1